Human respiratory syncytial virus vaccine

摘要

The present invention relates to RSV vaccines and methods for inducing an immune response to RSV in a subject comprising administering an RSV vaccine.

主权项

1. A vaccine composition comprising a purified human respiratory syncytial virus (RSV) strain L19 (RSV-L19) and a nanoemulsion adjuvant, wherein the nanoemulsion adjuvant inactivates the RSV virus, and wherein the nanoemulsion adjuvant comprises:
(a) droplets having an average diameter of less than about 1000 nm; (b) an aqueous phase; (c) about 1% to about 80% of at least one cosmetically or pharmaceutically acceptable oil; (d) about 0.001% to about 10% of at least one surfactant, wherein the surfactant is a polyoxyethylene nonionic surfactant, a cationic quaternary ammonium compound, or a combination thereof; and (e) about 0.1% to about 50% of at least one organic solvent, wherein the organic solvent is an alcohol.